

## **Director and Co-Company Secretary Resignation**

29 September 2017

Anteo Diagnostics Limited (ASX: ADO) ("**Anteo**" or "**Company**") today announces that Mr Richard Martin has today resigned from the Board and as Co-Company Secretary of the Company. The Board thanks Mr Martin for his service during his term.

Dr Hurrell, Executive Chairman, stated "The board is currently reviewing the strategic direction of the company and the skill set required by the Board to deliver shareholder value. In addition, the Company will be undertaking a recruitment process for a CEO. We thank Mr Martin for his service and wish him well in his future endeavours."

## ABOUT ANTEO GROUP - Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

For more information, please visit <a href="www.anteodx.com">www.anteodx.com</a>